InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Biogene gets bruised in ‘Battle of the skincare belles’
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
Biogene gets bruised in ‘Battle of the skincare belles’
2367.HK
688363.SHG
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
